MedTrace Logo

Esmolol for Myocardial Protection in Hypertrophic Obstructive Cardiomyopathy

NCT05073094 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2021-10-11

No results posted yet for this study

Summary

Perioperative blockage of beta-adrenoreceptors is widely used in cardiac and non-cardiac surgery to reduce the rate of cardiovascular complications. Several randomized-controlled studies and meta-analysis showed that esmolol reduces the incidence of myocardial ischemia and arrhythmias in cardiac surgery as well as enhances postoperative cardiac performance. No studies assessed the influence of esmolol in patients with hypertrophic obstructive cardiomyopathy undergoing cardiac surgery.

Conditions

  • Hypertrophic Obstructive Cardiomyopathy

Interventions

DRUG

Esmolol

Esmolol injected intravenously and added to cardioplegia solution

DRUG

Placebo

Equivalent volume of placebo (saline) as a bolus before aortic cross-clamping and in the cardioplegic solution

Sponsors & Collaborators

  • Meshalkin Research Institute of Pathology of Circulation

    lead NETWORK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-06
Primary Completion
2023-06-01
Completion
2023-07-01

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05073094 on ClinicalTrials.gov